[Special Stock] LabGenomics Soars on Expectations for Commercialization of COVID-19 Diagnostic Kit

[Asia Economy Reporter Minji Lee] LabGenomics is soaring on expectations for the commercialization of its COVID-19 diagnostic kit.

As of 3:11 PM on the 19th, LabGenomics is trading at 9,000 KRW, up 20.64% from the previous session.

LabGenomics plans to complete the development of its COVID-19 diagnostic kit and begin commercialization within this month.

On the previous day, molecular diagnostics specialist Seegene launched its COVID-19 diagnostic reagent in the domestic market.